secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001437749-24-009849
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra restates FY2021-22 financials due to warrant errors; FY2023 revenue $27.5M
--------------------------------------------------------------------------------

- Q4 2023 net revenue $13.2M (vs $2.2M); FY2023 net revenue $27.5M (vs $10.2M). Net loss FY2023 $46.0M.
- Non-cash restatement: warrant liability misclassified; FY2022 net income to increase ~$14.8M; material weakness expected.
- Acer acquisition completed Nov 2023; OLPRUVA launch underway; >70% commercial/government payor coverage.
- KP1077 Phase 2 IH study met safety endpoint; clinically meaningful sleepiness improvement; Phase 3 planning.
- Arimoclomol NDA PDUFA date Sept 21, 2024; FDA plans advisory committee. Cash $67.7M; runway into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924009849/0001437749-24-009849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924009849/zvra20230627c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-009849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer